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Background. Patients with WHO grade II glioma may respond to chemotherapy that is currently not standardized regarding timing
and treatment duration. Metabolic changes during chemotherapy may precede structural tumor volume reductions. We therefore
compared time courses of amino acid PET and MRI responses to temozolomide (TMZ) and assessed whether responses correlated
with seizure control and progression-free survival (PFS).
Methods. PET and MRI were performed before and during TMZ chemotherapy. Tumor volumes were calculated using regions-of-
interest analysis. Amino acid uptake was also quantified as metabolically active tumor volume and tumor-to-cerebellum uptake
ratio.
Results. One hundred twenty-five PET and 125 MRI scans from 33 patients were analyzed. Twenty-five patients showed metabolic
responses that exhibited an exponential time course with a 25% reduction of the active volume on average after 2.3 months. MRI
responses followed a linear course with a 25% reduction after 16.8 months. Reduction of metabolically active tumor volumes, but
not reduction of PET uptake ratios or MRI tumor volumes, correlated with improved seizure control following chemotherapy (P¼
.012). Receiver-operating-characteristic curve analysis showed that a decrease of the active tumor volume of ≥80.5% predicts a
PFS of ≥60 months (P¼ .018) and a decrease of ≥64.5% a PFS of ≥48 months (P¼ .037).
Conclusions. Amino acid PET is superior to MRI for evaluating TMZ responses in WHO grade II glioma patients. The response delay
between both imaging modalities favors amino acid PET for individually tailoring the duration of chemotherapy. Additional studies
should investigate whether this personalized approach is appropriate with regard to outcome.
Keywords: chemotherapy, epilepsy, low-grade glioma, MRI, PET.
Diffuse cerebral WHO grade II gliomas often present with epileptic
seizures and show insidious tumor growth.1 The natural history
and response to treatment of these tumors are predominantly
determined by genetic alterations such as co-deletion on chro-
mosomal arms 1p and 19q, isocitrate dehydrogenase 1 (IDH1/2)
mutation, and methylation of the O6-methylguanine-DNA methyl-
transferase (MGMT) promoter.2,3
Alkylating agent chemotherapy is effective in patients with
WHO grade II glioma. Once given at tumor progression or re-
currence, it yields objective response rates up to 60% and re-
sponse durations of several years.4 In addition, chemotherapy
can reduce the frequency of seizures. However, the evaluation
of chemotherapy response based on MRI with T2-weighted and
fluid-attenuated inversion recovery (FLAIR) MRI sequences is
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difficult.5 Accordingly, a reduction in seizure frequency has
been proposed as a surrogate marker for a clinical benefit
from chemotherapy.6,7 There is no current standard for the
optimal drug choice, timing, or duration of chemotherapy.
The European Organization for Research and Treatment of Can-
cer trial 22033-26033 prescribed 12 cycles of temozolomide
(TMZ) chemotherapy, while other groups treated patients as
long as MRI showed at least evidence of stable disease.4 Inter-
estingly, tumors may continue to shrink on MRI even after ter-
mination of chemotherapy.8,9 We have previously reported
WHO grade II glioma patients who experienced rapid metabolic
deactivation in response to TMZ, which was confirmed by using
PET with the amino acid O-(2-[18F]fluoroethyl)-L-tyrosine
(FET).10 Our current study aimed to investigate metabolic
responses in a large multicenter participant cohort treated
with TMZ. We also assessed whether metabolic responses
on PET correlate with seizure control and progression-free
survival (PFS).
Materials and Methods
Clinical Data
Participants were retrospectively identified according to the fol-
lowing criteria: (i) supratentorial cerebral WHO grade II glioma
at progression after surgery; (ii) no contrast enhancement on
T1-weighted MRI; (iii) no previous radio- or chemotherapy; (iv)
measurable disease on T2-weighted MRI before chemotherapy
with 2 perpendicular diameters ≥10 mm; and (v) MRI and
amino acid PET schedule including baseline evaluation and at
least 2 examinations during and at the end of chemotherapy.
Participant data were extracted from the hospital medical
records and included demographic as well as tumor and
treatment characteristics, PFS, and overall survival (OS).
Seizure frequencies before chemotherapy were documented
during postsurgical surveillance in every 3 months. Seizure
frequencies were recorded monthly during chemotherapy. We
defined seizure control groups during chemotherapy as: group
I¼ 0–50% seizure frequency reduction and group II¼.50%
reduction or seizure free.
Chemotherapy
TMZ chemotherapy was administered according to local poli-
cies (Table 1). Adverse effects were scored according to the
Common Terminology Criteria for Adverse Events (CTCAE,
version 4.0).
Imaging Data Acquisition
Baseline imaging was performed within one month before
chemotherapy initiation, and follow-up imaging started be-
tween 2 and 6 months thereafter. MRI examinations included
T2-weighted and gadolinium-enhanced T1-weighted sequenc-
es according to clinical routine protocols on 1.5 or 3.0 Tesla
MRI scanners. PET data were acquired after intravenous admin-
istration of 150–240 MBq FET (Switzerland, Austria, Germany)
or 650 MBq L-[methyl-11C]methionine (MET, Italy). Grosu
et al reported that both tracers yield virtually identical amino
acid uptake values in gliomas.11 Their whole cohort of patients
with WHO grade II-IV gliomas showed mean tumor-to-brain
uptake ratios of 2.5 for FET and of 2.6 for MET, which represent
a difference of 4%. Uptake ratios differed by 1% for the sub-
group of WHO II gliomas.11 We therefore consider both MET
and FET suitable to comparably characterize low-grade gliomas
on amino acid PET. Static emission scans were acquired at the
following time periods after tracer administration: 40–60 min-
utes (Switzerland; Discovery LS, GE Medical Systems), 30–
45 minutes (Austria; Advance, GE Healthcare), 20–40 minutes
(Germany; ECAT Exact HR+, Siemens), and 30–45 minutes
(Italy; Discovery LS, GE Healthcare). After correction for random
and scattered coincidences and dead time, images were recon-
structed with the specific scanner software. The reconstructed
image resolution was 5.5 mm.
Image Data Analysis, Determination of Response, and
Progression
Response assessment on PET and MRI was centrally performed
by M.Wy. (nuclear medicine) and U.R. and N.G. (neuro-
oncologists) with long-standing experience in PET and MRI
analysis. Each participant served as his or her own control,
and values during chemotherapy were expressed as percent
from baseline (ie, before the start of chemotherapy). Quantifi-
cation of PET and MRI data was performed on co-registered im-
ages using PMOD (PMOD Technologies Ltd).12 MRI tumor
volumes were measured on T2-weighted axial sequences by
manually outlining regions-of-interest (ROIs) around tissue ex-
hibiting T2-hyperintensity. Finally, all tumor-containing slices
were summed. Values during chemotherapy were expressed
as percent change from baseline MRI before the initiation of
chemotherapy. Response was also determined according to
the Response Assessment in Neuro-Oncology (RANO) criteria,
which quantify the product of the perpendicular tumor diame-
ters on the slice showing the largest tumor area (mm2).5 The
RANO criteria categorize size reductions between 25% and
50% as minor response, ≥50% as partial response, and disap-
pearance of the lesion on T2–weighted or FLAIR MR imaging as
complete response. Objective response is defined as the sum of
minor response, partial response, and complete response. Size
increases ≥25% were scored as progressive disease. Stable
disease was defined when MRI changes did not qualify for
progression or for complete, partial, or minor response. We
also diagnosed progression if new contrast enhancement on
T1-weighted sequences or clinical signs (eg, recurrence or
new onset of seizures) were accompanied by tumor size
increase ,25%.
Amino acid uptake was also quantified using ROI analysis.
The cerebellum served as reference region. ROIs covering the
whole cerebellum were drawn for each slice. Counts of all cer-
ebellar ROIs were then averaged to produce the mean cerebel-
lar amino acid uptake. Three measures were used for tumors.
First, the metabolically active volume (cm3) was calculated as
the tumor volume containing pixels .110% of the mean cere-
bellar amino acid uptake. We derived this threshold from our
earlier methodological study.13 It corresponds well with the
visual impression of active WHO grade II gliomas on PET.14
Second, the tumor amino acid uptake (counts) was determined
by placing a ROI over the tumor on the PET slice with the largest
extent, which was normalized to the mean cerebellar uptake
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(mean T-to-CBL ratio, unit-less). Third, peak uptake ratios were
calculated by averaging all counts from tumor voxels that ex-
hibited ≥95% of the maximum tumor radioactivity. In partici-
pants without active tumor volume, ROIs were placed on the
T2-weighted MR images and then transferred to the
corresponding PET planes. In line with our previous study,10
we defined a metabolic treatment response as a reduction
of ≥10% from the initial tumor volume (active PET volume)
on at least 2 subsequent time points at least 4 weeks apart
after the initiation of chemotherapy.
Table 1. Clinical data, histology and molecular genetic status, imaging response, and survival
ID Age (y) Histologya
WHO II
Extent of
surgery
IDH1a LOH
1p19qa
MGMTa TMZ dose
(mg)
PETb MRIb PFS (mo) OS (mo) Histologyc
(WHO grade)
1 37 A b mut no – 20’580 R (270) MR (231) 27 31 n.d.
2 49 A p – – – 67’620 R (256) SD (24) 24 31 n.d.
3 35 A p mut no m 29’400 R (221) MR (225) 38 75 n.d.
4 23 A b wt no m 70’560 R (294) SD (29) 19 21 GBM (IV)
5 38 A b wt no u 26’880 n.a.v. SD (21) 40 61 GBM (IV)
6 32 A p mut no u 20’160 NR (+354) SD (+18) 13 99+ A (II)
7 33 OA p mut no – 45’360 n.a.v. PD (+29) 16 27+ n.d.
8 38 OA p mut yes m 61’740 R (273) MR (240) 34 51+ n.d.
9 28 OA p mut no m 30’500 R (294) MR (239) 66 119+ OA (II)
10 27 OA p mut yes m 81’600 R (269) SD (210) 20 44 AA (III)
11 20 OA b mut no m 23’100 NR (28) SD (+0) 6 61+ OA (II)
12 31 OA p mut no m 58’100 R (299) SD (221) 73 125+ n.d.
13 40 OA b wt no u 53’200 NR (26) SD (220) 66 139+ n.d.
14 45 O b – – – 37’800 R (212) PR (267) 45 LFU n.d.
15 29 O gt – – – 24’500 R (291) MR (248) 17+ 17+ n.d.
16 41 O gt – – – 10’780 R (262) MR (234) 28 63+ O (III)
17 43 O gt – – – 8’250 R (298) SD (24) 61+ 61+ n.d.
18 36 O b – – – 13’000 R (229) SD (+2) 6 28+ n.d.
19 41 O b – – – 37’080 NR (+116) SD (+3) 24 44+ n.d.
20 40 O gt mut yes m 43’900 R (282) PR (276) 61 67+ n.d.
21 34 O b mut yes m 36’960 R (265) PR (261) 84 118+ n.d.
22 44 O p mut yes m 43’680 R (291) PR (257) 81+ 81+ n.d.
23 34 O gt mut yes m 29’820 R (298) PR (253) 66+ 66+ n.d.
24 51 O p wt no m 17’640 R (264) MR (242) 23 53 n.d.
25 38 O p mut yes m 17’640 R (272) MR (240) 36 61+ n.d.
26 45 O p mut yes m 26’420 R (267) SD (28) 10 68+ n.d.
27 37 O p mut no m 24’000 R (237) SD (+1) 7 74+ O (III)
28 51 O p mut yes m 108’000 n.a.v. SD (+2) 47+ 47+ n.d.
29 43 O gt mut yes m 85’600 NR (26) SD (+5) 6 8+ n.d.
30 53 O p mut yes m 42’300 R (256) SD (+6) 52+ 52+ n.d.
31 29 O p mut yes m 37’800 R (259) MR (242) 72+ 72+ n.d.
32 39 O p mut no m 12’750 R (227) SD (219) 47 73+ O (II)
33 34 O p mut yes u 33’500 R (279) SD (+9) 16 57+ n.d.
Abbreviations:
Histologya WHO grade II: A, astrocytoma; O, oligodendroglioma; OA, oligoastrocytoma; AA, anaplastic astrocytoma; n.d., not done.
Extent of surgery: b, biopsy; gt, gross total resection; p, partial resection.
IDH1, isocitrate dehydrogenase 1; mut, mutated; wt, wild type; –, no tissue available.
LOH, co-deletion on chromosomal arms 1p and 19q; no, absent; yes, present; –, no tissue available.
MGMT, O6-methylguanine-DNA methyltransferase; m, methylated; u, unmethylated; – , no tissue available.
PET: n.a.v., no active tumor volume; NR, nonresponder; R, responder.
MRI (RANO): MR, minor response; PD, progressive disease; PR, partial response; SD, stable disease.
PFS, progression-free survival; +, progression-free at end of follow-up.
OS, overall survival; LFU, lost during follow-up; +, alive at end of follow-up.
Histologyc (WHO grade): AA, anaplastic astrocytoma; A, astrocytoma; GBM, glioblastoma; n.d., not done; O, oligodendroglioma; OA, oligoastrocytoma.
alast operation before start of chemotherapy.
bnumber in bracket¼maximal volume decrease (2) or increase (+) in percent from baseline.
cafter progression following chemotherapy.
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Molecular Genetics
1p/19q co-deletion was assessed by fluorescence in situ hybrid-
ization and MGMT promoter methylation by methylation-specific
PCR. IDH1 status was determined by immunohistochemistry or
gene sequencing.
Statistics
We used descriptive statistics to characterize the patient popu-
lation. To test group-to-group differences, the Mann-Whitney U
test for independent samples was applied. The association be-
tween baseline imaging parameters and PFS was assessed
using the Spearman rank test. The prognostic value of the met-
abolically active tumor volume on PFS was assessed by
receiver-operating-characteristic (ROC) curve analyses. Partici-
pants were divided into responders (PFS ≥12, 24, 36, 48, or
60 months) and nonresponders (PFS ,12, 24, 36, 48, or 60
months). Decision cutoff was considered optimal when the
product of paired values for sensitivity and specificity reached
its maximum. Moreover, we determined the area under the
ROC curve (AUC), its standard error, and level of significance
as measures of diagnostic quality. In addition, we used uni-
and multivariate analyses including logistic regression to test
for associations of histology, PET and MRI response, and total
dose of TMZ as well as 1p/19q co-deletion, IDH1, and MGMT
status with PFS. PFS and OS were calculated from the start of
chemotherapy. Analyses were performed using SigmaStat soft-
ware (version 3.5; Systat Software, Inc.).
Ethics
Amino acid PET examinations are part of routine clinical inves-
tigations in WHO grade II glioma participants in Austria, Italy,
Switzerland, and Germany. All participants gave written in-
formed consent before each FET or MET PET investigation.
Signed consent is not required to perform clinical PET scans in
Switzerland. The local ethics committee of Innsbruck Medical
University approved this retrospective study. In Italy, local eth-
ics committee approval or patients’ signed consent is not re-
quired for retrospective data evaluation.
Results
Thirty-three participants with WHO grade II astrocytoma (n¼ 6),
oligodendroglioma (n¼ 20), or oligoastrocytoma (n¼ 7) were
enrolled (21 male and 12 female, mean age: 37+8 [SD] y,
range: 20–53 y). Prior to chemotherapy, 29 participants under-
went one, and 4 participants underwent 2 surgical procedures
(gross total resection in 6, partial resection in 18, biopsy in 9
participants, Table 1). During the entire study, no participant
received steroids, and no participant was treated with either pre-
vious radiotherapy or PCV (procarbazine-lomustine-vincristine)
chemotherapy.
Chemotherapy
TMZ chemotherapy started 40+36 months (range: 1–126 mo)
after the last operation because of radiological progression.
Chemotherapy was completed as scheduled in 17 participants
and was interrupted because of participant request, toxicity, or
progression in 1, 7, and 8 participants, respectively. Hematolog-
ical adverse effects of CTCAE grades 1, 2, or 3 were noted in 5,
3, and 8 participants, respectively. Nonhematological adverse
effects consisted of nausea in 8 participants (grades 1– 3),
fatigue in 6 (grades 2-3), anorexia in 2 (grades 1-2), pruritus
in 2 (grade 2), and local skin infection/zoster in 2 (grades
2-3). No secondary neoplasias were observed after a median
follow- up of 74 months.
Imaging
All participants from Italy were imaged with MET-PET (n¼ 9).
Participants from all other countries were imaged with FET-PET
(n¼ 24). One-hundred twenty-five PET scans and 125 MRI
scans were available for evaluation. On MRI, 14 participants
achieved an objective response (9 minor responses, 5 partial
responses) (Table 1). Baseline tumor volumes on T2-weighted
MRI ranged from 4.3–450.3 cm3 (75.7+103.9 cm3). Among
those 30 participants with baseline active tumor defined by
PET, volumes ranged from 1.4–269.9 cm3 (51.2+51.2 cm3).
In line with previous work,11 we found similar baseline mean
tumor uptake ratios for MET (1.43+0.27) and FET (1.42+
0.20). For histological subtypes, the following numbers were
found: T-to-CBL ratios were 1.43+0.24 in oligodendrogliomas,
1.43+0.27 in oligoastrocytomas, and 1.28+0.14 in astrocyto-
mas. Peak T-to-CBL ratios were 2.34+2.29 in oligodendroglio-
mas, 2.49+1.99 in oligoastrocytomas, and 1.80+1.58 in
astrocytomas. We found no active tumor volume at baseline
in 3 participants. In these patients, the median T-to-CBL ratio
was 1.04+0.02.
We identified 25 metabolic responders and 5 nonrespond-
ers. Examples of individual PET and MRI responses are present-
ed in Figure 1A. Metabolic responses during chemotherapy
were best described by an exponential time course, which yield-
ed a reduction of 25% after 2.3 months (Fig. 1B). In contrast,
MRI responses on T2-weighted images of the same participants
were delayed, followed a linear decrease, and showed a volume
reduction of 25% at 16.8 months after initiation of chemother-
apy (Fig. 1C). During chemotherapy, the mean and peak
T-to-CBL ratios in PET responders were reduced in 7 participants
by 10%–21%. The remaining participants showed decreases
of ,7%, most likely indicating that successful chemotherapy
reduced the spatial extent of tumor burden (ie, the active
tumor volume) but not the histology or WHO tumor grade. In
contrast to the responses of the active tumor volume,
T-to-CBL ratios did not follow a linear or exponential fit (data
not shown).
In PET, nonresponding participants’ active tumor volumes
increased within 6 months up to 354% from baseline. The
mean T-to-CBL ratios increased by 7%–11%, and the peak
T-to-CBL ratios increased by 14%–36%. All tumors without
active volume remained metabolically inactive during chemo-
therapy, and T-to-CBL ratios remained in a range between
96% and 103% from baseline.
Molecular Genetic Data
Information on IDH1 status and LOH1p/19q was available for
26 participants each, and MGMT promoter methylation was
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available for 24 participants (Table 1). Twenty-two (85%)
tumors showed IDH1 mutation, 13 (50%) had 1p/19q
co-deletion, and 20 (83%) had MGMT promoter methylation.
PET responders exhibited IDH1 mutation in 17 (77%) partici-
pants, 1p19q co-deleted tumors in 11 (85%) participants,
and MGMT promoter methylation in 17 (85%) participants.
Seizures
Twenty-two participants presented with seizures before che-
motherapy. Tumor size on MRI, active PET tumor volume, and
tumor uptake ratios at baseline were balanced between the 2
seizure response groups (Table 2). During chemotherapy, anti-
epileptic drug doses were changed to account for low drug
serum concentration or for persisting seizures in 5 participants,
and were stable in 17 participants. No participant experienced
an increase in seizure frequency during chemotherapy. Nine
participants experienced seizure frequency reductions by 0%–
50% and 6 participants by .50%, while 7 participants were
seizure-free. Among the 17 participants under stable antiepi-
leptic drug doses, TMZ reduced the active tumor volumes by
22%+27% in group I participants and by 64%+28% in
group II participants (Fig. 2A, P¼ .012, Mann-Whitney test).
In contrast, neither T-to-CBL ratio changes nor volume changes
on T2-weighted MRI images corresponded with seizure fre-
quency reductions (Fig. 2B and C).
Survival
At the time of last follow-up, 25 participants were alive, 7 had
died, and one was lost to follow-up. Twenty-six participants
progressed at 33+22 months (range: 6 –85 mo) after the
start of chemotherapy, while 7 participants were free from pro-
gression at 42+22 months (range: 6–68 mo). Progression was
characterized by neurological deterioration in 23 participants,
by increase of the T2 lesion in 24 participants, and by appear-
ance of new contrast enhancement in 14 participants, respec-
tively. Nine participants underwent re-operation for progressive
tumor (Table 1). Of the progressing participants, 7 died 45+19
months (range: 21–75 mo) after starting chemotherapy.
Neither the mean nor the peak T-to-CBL ratio nor the magni-
tude of active tumor volumes prior to chemotherapy was predic-
tive for PFS (P¼ .551, P¼ .748, and P¼ .622, respectively). In
participants with active tumor volume (n¼ 30), the median PFS
was not significantly different between metabolic responders
(34.3+21.8 mo, range: 6–85 mo) and nonresponders (27.6+
27.2 mo, range: 6–67 mo) (P¼ .605). In contrast, ROC analysis
yielded a decrease of the active tumor volume of ≥80.5% as
an optimal cutoff for the prognostication of a PFS ≥60 months
(sensitivity 67%, specificity 90%, accuracy 83%, AUC 0.78+
0.02, P¼ .018). For the prognostication of a PFS ≥48 months, a
decrease of the active tumor volume of≥64.5% was the optimal
threshold (sensitivity 70%, specificity 58%, accuracy 62%, AUC
0.74+0.11, P¼ .037). The prognostication of a PFS ≥36 months
(P¼ .154), ≥24 months (P¼ .369), and ≥12 months (P¼ .057),
respectively, was not significant.
Fig. 1. Time course of imaging responses. (A) Examples of individual responses as measured with PET (filled symbols) and MRI (open symbols).
Square: oligoastrocytoma (#12); triangle: oligodendroglioma (#16); diamond: astrocytoma (#6). (B and C) Data points represent pooled volume
changes measured for the whole cohort of metabolic responders during chemotherapy before progression (ie, participants were censored at the
last PET or MRI prior to progression. Black lines correspond to exponential fit for PET data (B) (y¼ 74.61 * exp(2x/158.86)+ 24.31) and linear fit for
MRI data (C) (y¼ 99.27–0.05 * x), respectively. Values on the y-axis represent percent volume changes compared with baseline (ie, before the start
of chemotherapy).
Table 2. Baseline characteristics according to seizure frequency
reduction groups
Group I Group II
n 9 13
Tumor localization
Frontal (n) 4 5
Temporal (n) 0 6
Parietal (n) 5 2
Tumor size on MRIa 57+96 60+57
Active PET tumor volumea 51+90 47+40
Mean T-to-CBL uptake ratio 1.34+0.32 1.40+0.16
Peak T-to-CBL uptake ratio 2.37+1.40 2.30+0.48
Patient groups refer to the maximal percent reduction of seizure
frequency during chemotherapy: group I¼ 0–50%, II¼ 51–99% or
seizure-free.
aVolumes are presented in cm3. T-to-CBL¼ tumor-to-cerebellum
uptake ratio (unit-less) (mean+SD).
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The PFS in participants without active tumor volume was
29.1+12.4 months (range: 17–41 mo). None of the following
parameters correlated with PFS, either on univariate or multi-
variate analysis: histology (oligodendroglial/oligoastrocytic vs
astrocytic tumor, P¼ .988), PET (responder vs nonresponder,
P¼ .734), MRI (objective response [RANO], P¼ .276), total TMZ
dose (P¼ .100), IDH1 status (P¼ .088), 1p/19q co-deletion (P¼
.331), MGMT promoter methylation status (P¼ .672) (P values
shown for univariate analysis). In addition group-to-group com-
parisons (imaging responses) did not show differences between
tumors with or without IDH mutation, between tumors with or
without co-deletion 1p19q, or between tumors with methylated
or unmethylated MGMT promotor (Mann-Whitney U test, P. .5
for all comparisons). This may, in part, be explained by the
small subgroups compared within this test.
Discussion
In line with previous reports on patients with diffuse cerebral
WHO grade II gliomas, we have observed that chemotherapy
responses on MRI occur with variable delay from the initiation
of treatment.8,9 We noticed a 25% tumor volume reduction on
MRI after 16.8 months, whereas a 25% reduction of the meta-
bolically active tumor volume on PET was observed as early as
2.3 months after initiation of chemotherapy. We excluded par-
ticipants with enhancing tumors on MRI because blood-brain
barrier disruption contributes to nonspecific imaging results
through passive radiotracer influx into the tumor. Thus, we
can assume that the amino acid PET signal in our participants
is specific for active amino acid uptake,15,16 which for MET and
FET is largely mediated by the L-amino acid transport system.17
Accordingly, TMZ chemotherapy appears to downregulate ac-
tive amino acid transport in WHO grade II gliomas as an
early response indicator. Altogether, 83% of our participants
with active tumor volume were PET responders following expo-
sure to TMZ. The long delay between PET and MRI responses
may reflect that amino acid transporters represent a sensitive
nutritional part of tumor cell metabolism, whereas signal ab-
normalities on MRI T2-weighted sequences, which may relate
to tumor cell densities, edema, and alteration of the extracel-
lular matrix, respond slowly to cytotoxic therapy.
Apart from tumor control, TMZ chemotherapy resulted in
improved seizure control. To the best of our knowledge, this is
the first study showing that seizure control corresponds to the
magnitude of active tumor volume reductions on amino acid
PET. Of note, seizure control was neither paralleled by changes
in amino acid uptake ratios nor by decreases of tumor volumes
as measured by MRI. The latter is in line with recent observa-
tions in patients with WHO grade II gliomas treated with either
radiotherapy18 or TMZ.7 Thus, improved seizure control may not
rely exclusively on reduced compression of neuronal structures
by the tumor but also on the reduction of magnitude and spa-
tial extent of local metabolic disequilibrium. The mechanisms
behind improved seizure control may involve the glutamatergic
system. Gliomas release glutamate as an excitatory neuro-
transmitter and activate neuronal glutamate receptors.19,20
FET uptake is increased during status epilepticus in the cortex
adjacent to gliomas and resolves after cessation of epileptic ac-
tivity.21 Whether transport of both types of amino acids, which
use different transport systems under physiological conditions,
relates to each other in gliomas remains to be evaluated.
The main limitation of our study is its retrospective nature
and small sample size. Moreover, there was heterogeneity of
TMZ regimens and PET and MRI scanners, and molecular data
were not available for all participants. The variability of TMZ reg-
imens reflects the current lack of evidence-based recommen-
dations regarding the optimal regimen and duration of
chemotherapy.22 However, based on our results, we assume
that the time delay between amino acid PET and MRI response
may be clinically meaningful. Individual PET-guided determina-
tion of chemotherapy duration in patients showing an early
metabolic response and response plateau could reduce the
risk of toxicity and lower treatment burden and costs. Moreover,
one should be cautious about overtreating patients with alkyl-
ating chemotherapy, which can exert a mutagenic effect influ-
encing the risk of malignant transformation.23,24 In conclusion,
here we have characterized the patterns of chemotherapy re-
sponse on amino acid PET in a cohort of patients with diffuse
cerebral WHO grade II gliomas and report a positive correlation
between active tumor volume responses, PFS, and seizure con-
trol. A prospective study should validate our findings including
MRI, dynamic amino acid PET,25 and molecular markers to
determine whether personalized PET-guided management
Fig. 2. Seizure control and imaging responses. Best imaging responses on active PET volume (A), mean T-to-CBL uptake ratio (B), MRI T2 lesion size
(C) in patients under stable antiepileptic drug doses (n¼ 17). Seizure control group I¼ reduction of seizure frequency by 0%–50%, seizure control
group II¼ reduction .50% or seizure-free patients during chemotherapy. Figure 2A: *P¼ .012 (Mann-Whitney U test).
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has impact on survival. With regard to the choice of amino acid
PET tracer, FET currently seems to be the most promising.26 For
the purpose of assessing response to chemotherapy, FET up-
take should be quantified as metabolically active volume. This
may represent a useful approach to patients with WHO grade II
gliomas, a rare disease with substantial variation of the clinical
course and treatment response.
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